| Autoimmune thyroid disease |
2.24 |
0.00e+0 |
46/53 (86.79%) |
PRF1;GZMB;HLA-DRA;...
|
| Allograft rejection |
2.24 |
0.00e+0 |
32/38 (84.21%) |
PRF1;GZMB;HLA-DRA;...
|
| Graft-versus-host disease |
2.17 |
0.00e+0 |
32/42 (76.19%) |
PRF1;GZMB;KLRD1;...
|
| Viral protein interaction with cytokine and cytokine re... |
2.06 |
2.82e-3 |
84/100 (84%) |
TNFSF10;CXCL10;CCL5;...
|
| Viral myocarditis |
2.00 |
2.26e-3 |
53/60 (88.33%) |
PRF1;ITGAL;HLA-DRA;...
|
| Asthma |
1.97 |
3.76e-3 |
25/31 (80.65%) |
FCER1G;HLA-DRA;HLA-DRB1;...
|
| Cytosolic DNA-sensing pathway |
1.95 |
3.22e-3 |
52/63 (82.54%) |
CXCL10;CCL5;AIM2;...
|
| Hematopoietic cell lineage |
1.92 |
2.82e-3 |
90/99 (90.91%) |
CD3E;CD14;CD3D;...
|
| Influenza A |
1.92 |
2.51e-3 |
156/172 (90.7%) |
TNFSF10;CXCL10;CCL5;...
|
| RIG-I-like receptor signaling pathway |
1.87 |
5.64e-3 |
64/70 (91.43%) |
CXCL10;CASP10;IKBKE;...
|
| Natural killer cell mediated cytotoxicity |
1.81 |
1.23e-2 |
99/131 (75.57%) |
TNFSF10;PRF1;PIK3CA;...
|
| Th1 and Th2 cell differentiation |
1.80 |
1.50e-2 |
80/92 (86.96%) |
RUNX3;IL2RB;STAT4;...
|
| Cytokine-cytokine receptor interaction |
1.78 |
1.65e-2 |
246/295 (83.39%) |
TNFSF10;CXCL10;CCL5;...
|
| JAK-STAT signaling pathway |
1.76 |
1.69e-2 |
146/162 (90.12%) |
PIK3CA;IL2RB;STAT4;...
|
| Epstein-Barr virus infection |
1.76 |
1.65e-2 |
189/202 (93.56%) |
CXCL10;RUNX3;RELB;...
|
| Intestinal immune network for IgA production |
1.75 |
1.62e-2 |
38/48 (79.17%) |
HLA-DRA;IL6;TNFRSF17;...
|
| Antigen processing and presentation |
1.72 |
2.59e-2 |
60/78 (76.92%) |
HSPA2;CD8A;KLRD1;...
|
| Primary immunodeficiency |
1.71 |
2.51e-2 |
33/38 (86.84%) |
CD3E;CD3D;CD8A;...
|
| TNF signaling pathway |
1.71 |
2.61e-2 |
103/112 (91.96%) |
CXCL10;CCL5;PIK3CA;...
|
| Chemokine signaling pathway |
1.70 |
2.88e-2 |
163/192 (84.9%) |
CXCL10;CCL5;ITK;...
|
| NOD-like receptor signaling pathway |
1.68 |
3.22e-2 |
145/181 (80.11%) |
CCL5;AIM2;RHOA;...
|
| Bacterial invasion of epithelial cells |
1.67 |
3.69e-2 |
59/77 (76.62%) |
PIK3CA;RHOA;PXN;...
|
| Amoebiasis |
1.66 |
3.58e-2 |
99/102 (97.06%) |
PIK3CA;SERPINB9;CD14;...
|
| Hepatitis C |
1.65 |
4.13e-2 |
139/157 (88.54%) |
CXCL10;PIK3CA;CLDN8;...
|
| Leukocyte transendothelial migration |
1.64 |
4.51e-2 |
90/114 (78.95%) |
ITK;PIK3CA;RHOH;...
|
| T cell receptor signaling pathway |
1.62 |
4.73e-2 |
93/104 (89.42%) |
ITK;PIK3CA;CD3E;...
|
| Toll-like receptor signaling pathway |
1.61 |
4.89e-2 |
94/104 (90.38%) |
CXCL10;CCL5;PIK3CA;...
|
| GnRH secretion |
1.60 |
4.95e-2 |
60/64 (93.75%) |
PIK3CA;GPER1;ITPR1;...
|